- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 12
- States / cities
- Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 632
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Antibiotics Causing Adverse Effects in Therapeutic Use
- Interventions
- Chart Review
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 5,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 12
- States / cities
- Sedona, Arizona • Denver, Colorado • Arlington Heights, Illinois + 8 more
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
- Interventions
- Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bannockburn, Illinois
- Conditions
- Rheumatoid Arthritis
- Interventions
- SAN-300 0.5 mg/kg QW, SAN-300 1.0 mg/kg QW, SAN-300 2.0 mg/kg QOW, SAN-300 4.0 mg/kg QOW, SAN-300 4.0 mg/kg QW, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • El Cajon, California • Los Angeles, California + 9 more
- Conditions
- Healthy
- Interventions
- Cohort A, Cohort B, Cohort C, Cohort D
- Biological
- Lead sponsor
- Uniquity One (UNI)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hematologic Neoplasms
- Interventions
- BMS-986016, BMS-936558
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 8
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more
- Conditions
- Astrocytoma, Glioblastoma, Progressive Disease
- Interventions
- FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
- Biological · Procedure · Diagnostic Test
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Interventions
- Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B, Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B, Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B, Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B, Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A
- Other
- Lead sponsor
- British American Tobacco (Investments) Limited
- Industry
- Eligibility
- 26 Years to 55 Years
- Enrollment
- 806 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 18
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 14 more
- Conditions
- Breast Cancer
- Interventions
- Amcenestrant, Palbociclib, Alpelisib, Everolimus, Abemaciclib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Solid Tumor
- Interventions
- LY3415244
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
- Interventions
- LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2036
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
- Conditions
- Renal Impairment, Healthy
- Interventions
- ALXN2050
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Hialeah, Florida • Orlando, Florida
- Conditions
- NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
- Interventions
- MYTX-011
- Drug
- Lead sponsor
- Mythic Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Newport Beach, California + 13 more
- Conditions
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Interventions
- TAS6417, CYP Cocktail, Transporter Cocktail
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more
- Conditions
- Cerebral Palsy
- Interventions
- Not listed
- Lead sponsor
- Holland Bloorview Kids Rehabilitation Hospital
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 9
- States / cities
- Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 5 more
- Conditions
- Metabolic Syndrome
- Interventions
- Professional nutrition counseling, No professional nutrition counseling
- Other
- Lead sponsor
- Madigan Army Medical Center
- Federal
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Budoprutug
- Drug
- Lead sponsor
- Climb Bio, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Allen, Texas • San Antonio, Texas
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Interventions
- Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • St Louis, Missouri • Nashville, Tennessee
- Conditions
- Solid Cancers, Non-Hodgkin's Lymphoma
- Interventions
- Fulvestrant, GDC-0032, Letrozole, Midazolam
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more
- Conditions
- Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
- Interventions
- Nivolumab, Cisplatin, Pemetrexed Disodium, Gemcitabine Hydrochloride
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Abington, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Embolism and Thrombosis, Infection, Inflammation
- Interventions
- Venepuncture, Fingerstick
- Diagnostic Test
- Lead sponsor
- LumiraDx UK Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Banning, California • Northglenn, Colorado • Wichita, Kansas + 1 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Illuminare-1, Karl Storz D-Light C photodynamic diagnostic (PDD)
- Drug · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
- Conditions
- Neoplasms, Neoplasm Metastasis, Lymphoma
- Interventions
- LY3039478, Prednisone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more